Abstract Library

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Siebenhüner A

Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,

Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,

#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression

Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,

Keywords: neuroendocrine, estrogen, progesterone, clinical trial,

#2051 Do We Need Hormonal Therapy for Pancreatic Neuroendocrine Tumors? An Effort to Reduce the Size of PanNETs

Introduction: Pancreatic neuroendocrine tumors although rare , have been significantly increased over the past few decades. They range from indolent to highly aggressive in nature. Just like breast and endometrial carcinoma are hormonal dependant,

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: high positive ERβ, Hormonal therapy, small size PanNET,

#1592 Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Approach to the Special Type of Breast Malignancy

Introduction: WHO classification from 2003 defines primary neuroendocrine carcinomas (NEC) of the breast as a group of tumors with expression of neuroendocrine markers in more than 50% of tumor cells. In the current WHO classification this category is renamed to “carcinomas with neuroendocrine features” without defined clear-cut of the percentage of tumor cells positive for neuroendocrine markers.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Demirovic A

Authors: Demirović A, Vranic S, Skenderi F, Peric Balja M, Ulamec M,

Keywords: breast cancer, special types, carcinoma with neuroendocrine features, neuroendocrine markers,

#1544 Immunohistochemical Expression of Estrogen and Progesterone Receptors in Neuroendocrine Tumors

Introduction: Expression of progesterone (PR) and estrogen receptor (ER) in some neuroendocrine tumors (NET) raises the possibility of hormonal regulation in these tumors, but those prevalence and clinical implication are unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Silva M

Authors: Costa D, Albuquerque C, Boente L, Araujo D, Fares A,

Keywords: progesterone, estrogen, carcinoid,